Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04971837
Other study ID # 21-10634H
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 20, 2021
Est. completion date December 9, 2021

Study information

Verified date June 2022
Source Colorado State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to a recent consumer poll, over 20 million Americans regularly use cannabidiol (CBD). Moreover, 64 million Americans (over 25% of the population) report trying CBD at least once within the previous 2 years. Since the passing of the 2018 Agriculture Improvement Act, the use of hemp-derived products, such as CBD, is highly prevalent across North America. The acceleration of the use of CBD has outpaced our understanding of the associated potential risks and benefits, and the way it is processed within the body. In the current proposed project, investigators wish to continue our ongoing collaboration with Caliper Foods, a Colorado-based manufacturer of CBD products. The focus of this project is three-fold: (1) investigators will compare the pharmacokinetics of different formulations of ingestible CBD; (2) investigators will examine the potential two-way interaction between a meal and one formulation of ingestible CBD; and, (3) investigators will examine the influence of different formulations of CBD on markers of liver function.


Description:

Pharmacokinetics describes the speed in which something that is ingested is made available within the body (i.e. bioavailability).There are many different preparations/formulations of CBD and they may differ from one another with regards to their pharmacokinetics. One important consideration when evaluating CBD formulations is the pharmacokinetic goal and intended use. For example, if the indication for the CBD is to treat acute pain, then a faster time to peak concentration (Tmax) and higher maximal concentration (Cmax) may be desirable, and also may help to decrease the risk of overdose due to premature repeat self administration. Alternatively, as a chronic treatment for anxiety, a larger area under the curve (AUC) may be preferable if a user follows a regular dosing schedule. One purpose of the proposed project is to compare the pharmacokinetics of different formulations of CBD. The formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). Several previous studies have demonstrated an influence of eating on the pharmacokinetics of ingested CBD. The general consensus appears to be that prior ingestion of a high-fat meal increases the maximal concentration of circulating CBD (Cmax) and lowers the time to attain peak circulating concentration (Tmax). One purpose of the proposed project is to study the influence of a standardized meal on the pharmacokinetics of a CBD formulation. Little is known about the influence of ingested CBD on postprandial metabolism. The thermic effect of feeding (i.e. the increase in metabolic rate above resting metabolism) is considered an important physiological determinant of energy balance, and therefore also of weight gain or loss. Further, the dynamics of circulating glucose and triglycerides following a meal are reflective of metabolic health and predictive of future cardiometabolic disease risk. CBD has been purported to have a variety of beneficial physiological properties, including anti-inflammatory and antioxidant actions. Either of these individual properties alone could favorably modify postprandial metabolism, given that CBD potentially does both, it appears likely that CBD might improve the physiological regulation of postprandial metabolism. One purpose of the proposed project is to determine the influence of CBD on postprandial metabolism. The liver plays a critical regulatory role in postprandial metabolism, and also with the physiological processing of cannabinoids. The relationship between the use of cannabinoids and liver health is unclear. While early studies implied that exposure of the liver to very high daily dosing of cannabinoids may be detrimental, more recent studies are suggesting that some cannabinoids, including CBD, may have therapeutic potential for the treatment of non-alcoholic fatty liver disease. The acute effects of low dose CBD (e.g. 30 mg) on liver function in healthy adults have not been well described, and may be influenced by the formulation of the CBD product (i.e. whether it is water or lipid soluble). One purpose of the proposed project is to determine the acute influence of different formulations of CBD on circulating markers of liver function.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date December 9, 2021
Est. primary completion date December 9, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must be greater than 18 years of age - Weigh more than 110 pounds - Have a body mass index greater than 25kg/m^2 - Be free of any gastrointestinal or metabolic diseases - Be able to refrain from use of any Cannabis or cannabis containing products for three days prior to participating in the study. Exclusion Criteria: - Less than 18 years of age - Pregnant or breastfeeding - Food allergies - Autoimmune disorders or with compromised immune function, - Celiac disease - Inflammatory bowel Diseases - Gastrointestinal cancers - Diabetes - HIV - Adverse reactions to ingesting Cannabis spp. or cannabis-containing products (including, but not limited to, marijuana, CBD oils, or CBD/THC containing food products) - Taking any of the follow medications: steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, HIV antivirals, immune modulators, benzodiazepines, antiarrythmics, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotension II blockers, oral hypoglycemic agents, and sulfonylureas.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Cannabidiol (CBD) powder formulation
T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
Cannabidiol (CBD) Oil based tincture formulation
30 mg CBD isolate in MCT oil (1:1 ratio of CBD to Medium Chain Triglycerides oil)
Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation
10% CBD Gum Arabic, maltodextrin base
Cannabidiol (CBD) Gum Arabic, sorbitol base formulation
10% CBD Gum Arabic, sorbitol base
Cannabidiol (CBD) Isolate in water formulation
formulation
CBD matching Placebo
Matching Placebo

Locations

Country Name City State
United States Colorado State University, Dept. of Health and Exercise Science Fort Collins Colorado

Sponsors (1)

Lead Sponsor Collaborator
Colorado State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare different formulations of CBD Pharmacokinetic Time to Maximum Concentration- (Tmax) The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate Tmax (hours). Venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic maximum concentration-(Cmax). The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate Cmax (ng/mL). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic area under the curve representing total cannabidiol exposure between 0 and 4 h (AUC 0-4) The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate AUC 0-4 (h x ng/mL). Venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic area under the curve an estimate of total exposure to CBD over time (AUC 0-inf). The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate AUC 0-inf (h x ng/mL). Venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic amount of time it takes to decrease the circulating concentration to half of its initial value (t1/2). The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate t1/2 (h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic rate at which CBD is absorbed into the body (Ka). The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate Ka(1/h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic rate at which CBD is removed from the body (Ke). The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate Ke (1/h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Compare different formulations of CBD Pharmacokinetic volume of distribution- (Vd) The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be sampled at standardized intervals over 4-hours to calculate Vd (L). Venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter Tmax of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts the time to attain peak circulating concentration Tmax (h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter Cmax of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD Cmax (ng/L). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter AUC 0-4 of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD AUC 0-4 (hxng/mL). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter AUC 0-inf of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD AUC 0-inf (hxng/mL). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter t1/2 of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD t1/2 (h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter Ka of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD Ka (1/h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter Ke of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD Ke (1/h). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine the Pharmacokinetic parameter Vd of a T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate after standardized meal At the 2 randomized visits Including a Test Meal, determine if a high-fat meal impacts maximal concentration of circulating CBD Vd (L). venous blood will be sampled at standardized intervals over 4-hours: 0, 10, 20, 30, 45, 60, 120, 180, and 240 minutes and will be analyzed to compare circulating CBD concentration.
Primary Determine ingested CBD on postprandial metabolism via indirect calorimetry At the 2 randomized visits Including a Test Meal measure resting metabolic rate (RMR- kcal/day) followed immediately by ingestion of a liquid meal and a single 30 mg dose of Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate or a placebo. Change from the 2 randomized visits Including a test meal separated by 4 days
Primary Determine ingested CBD on postprandial metabolism via measurements of glucose At the 2 randomized visits Including a Test Meal measure blood glucose at standardized intervals after ingestion of a liquid meal and a single dose of Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate or a placebo. Compare 2 randomized visits Including a test meal collected at 90,150,210,725 minutes.
Primary Determine ingested CBD on postprandial metabolism via measurements of insulin At the 2 randomized visits Including a Test Meal measure insulin at standardized intervals after ingestion of a liquid meal and a single dose of Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate or a placebo. Compare 2 randomized visits Including a test meal collected at 90,150,210,725 minutes.
Primary Determine ingested CBD on postprandial metabolism via measurements of triglycerides At the 2 randomized visits Including a Test Meal measure triglycerides at standardized intervals after ingestion of a liquid meal and a single dose of Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate or a placebo. Compare 2 randomized visits Including a test meal collected at 90,150,210,725 minutes.
Primary Determine the change in the acute influence of liver function, alanine aminotransferase (ALT), with the different formulations of CBD. The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be collected at standardized intervals and analyzed for alanine aminotransferase (ALT). Change from baseline at time 0, 60, 120 minutes for each formulation, visits separated by 14 days
Primary Determine the change in the acute influence of liver function, albumin, with the different formulations of CBD. The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be collected at standardized intervals and analyzed for albumin. Change from baseline at time 0, 60, 120 minutes for each formulation, visits separated by 14 days
Primary Determine the change in the acute influence of liver function, alkaline phosphatase, with the different formulations of CBD. The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be collected at standardized intervals and analyzed for alkaline phosphatase. Change from baseline at time 0, 60, 120 minutes for each formulation, visits separated by 14 days
Primary Determine the change in the acute influence of liver function, aspartate aminotransferase, with the different formulations of CBD. The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be collected at standardized intervals and analyzed for aspartate aminotransferase. Change from baseline at time 0, 60, 120 minutes for each formulation, visits separated by 14 days
Primary Determine the change in the acute influence of liver function, total bilirubin, with the different formulations of CBD. The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be collected at standardized intervals and analyzed for total bilirubin. Change from baseline at time 0, 60, 120 minutes for each formulation, visits separated by 14 days
Primary Determine the change in the acute influence of kidney function, blood urea, with the different formulations of CBD. The different formulations will be standardized for CBD dose (30 mg) but will differ in their preparation (e.g. water vs. fat-soluble). At the 5 randomized Visits Not Including A Test Meal venous blood will be collected at standardized intervals and analyzed for blood urea. Change from baseline at time 0, 60, 120 minutes for each formulation, visits separated by 14 days
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1